CG Oncology (CGON) Payables (2023 - 2026)

CG Oncology's Payables history runs 4 years deep, the most recent figure standing at $8.2 million for Q1 2026.

• Quarterly Payables rose 22.36% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 22.36% YoY) and the FY2025 annual result came in at $5.7 million, down 12.32% from the prior year.
• Payables was $8.2 million for Q1 2026 at CG Oncology, up from $5.7 million in the prior quarter.
• Across five years, Payables topped out at $9.2 million in Q3 2025 and bottomed at $3.2 million in Q4 2023.
• A 4-year average of $6.0 million and a median of $6.1 million in 2024 frame the typical range for Payables.
• Peak annual rise in Payables reached 125.54% in 2025, while the deepest fall reached 12.32% in 2025.
• CG Oncology's Payables stood at $3.2 million in 2023, then soared by 101.02% to $6.5 million in 2024, then decreased by 12.32% to $5.7 million in 2025, then soared by 44.14% to $8.2 million in 2026.
• Business Quant data shows CGON's Payables at $8.2 million in Q1 2026, $5.7 million in Q4 2025, and $9.2 million in Q3 2025.